
## **Supplementary Appendix**

Supplement to: Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN trial): progression-free survival by independent review and overall survival update.

## List of participating sites Institute, Investigator [Number of patients]

Dana-Farber Cancer Institute, Toni Choueiri [16] Washington University School of Medicine, Joel Picus [12] The Ohio State University, J. Paul Monk III [10] West Michigan Cancer Center, Kathleen Yost; Sunil Nagpal (former PI) [5] University of Iowa/Holden Comprehensive Cancer Center, Laith Abushahin; Daniel Vaena (former PI) [4] Duke University Medical Center, Jeffrey Crawford [4] Medical University of South Carolina, Harry Drabkin [4] Wake Forest Baptist Health, Christopher Thomas [4] Mayo Clinic - Rochester, Brian Costello [3] Cancer Center of Kansas - Wichita (Main), Shaker Dakhil [3] Oklahoma Cancer Specialists and Research Institute-Tulsa, Mark Roger Olsen [3] Virginia Commonwealth University/Massey Cancer Center, Asit Paul; Craig Swainey (former PI) [3] University of Chicago Comprehensive Cancer Center, Walter Stadler [3] University of Kentucky/ Markey Cancer Center, Peng Wang; Dennie Vance Jones (former PI) [3] Park Nicollet- Saint Louis Park (Metro MN), Daniel Anderson [2] Southeastern Medical Oncology Center, James Atkins [2] McLeod Regional Medical Center, Rajesh Bajaj [2] Mercy Hospital Springfield, Jay Carlson [2] Massachusetts General Hospital Cancer Center, Toni Choueiri [2] Montefiore Medical Center, Benjamin Gartrell [2] Hackensack University Medical Center, Samuel Goldlust [2] Southern Cancer Center, Brian Heller [2] Hematology- Oncology Associates of Central New York, Jeffrey Kirshner [2] Memorial University Medical Center, Harvey Lebos [2] McFarland Clinic, Joseph Merchant [2] Columbus Oncology and Hematology Associates Inc, Timothy Moore; John P Kuebler (former PI) [2] Flower Hospital, Jeffrey Muler [2] MedStar Georgetown University Hospital, George Philips [2] Saint Joseph Mercy Hospital, Christopher Reynolds [2] VA Western NY Healthcare System, Lynn Steinbrenner [2] Siouxland Regional Cancer Center, Donald Wender [2] Regions Hospital (Metro MN), Daniel Anderson [1] Fairview- Southdale Hospital (Metro MN), Daniel Anderson [1] Saint Francis Regional Medical Center (Metro MN), Daniel Anderson [1] Minnesota Oncology and Hematology PA-Woodbury, Daniel Anderson [1] Lakeview Hospital, Daniel Anderson [1] University of Oklahoma Health Sciences Center, Adam Asch; Carla Kurkjian (former PI) [1] Queen's Medical Center, Jeffrey Berenberg [1]

Straub Clinic and Hospital, Jeffrey Berenberg [1] Froedtert and Medical College of Wisconsin, Kathryn Bylow [1] Mercy Hospital Oklahoma City, Vikki Canfield [1] Providence Portland Medical Center, Alison K Conlin [1] Cancer Center of Kansas - Dodge City (Wichita), Shaker Dakhil [1] Nevada Cancer Research Foundation, John Ellerton [1] Missouri Baptist Medical Center, Bryan Faller; Alan Lyss (former PI) [1] Memorial Sloan Kettering Cancer Center, Darren Feldman; Michael Morris (former PI) [1] Roswell Park Cancer Institute, Saby George [1] Glens Falls Hospital, Aqeel Gillani [1] Kettering Medical Center, Howard Gross [1] Blanchard Valley Hospital, Howard Gross [1] Green Bay Oncology - Escanaba, Anthony J Jaslowski [1] Green Bay Oncology Limited at Saint Mary's Hospital, Anthony J Jaslowski [1] Guthrie Medical Group PC/Robert Packer Hospital, Bradley Lash; Edward T O'Brien (former PI); Philip Lowry (former PI) [1] University of New Mexico (UNM) Comprehensive Cancer Center, Richard Lauer [1] Columbia University Medical Center, Emerson Lim; Bret Taback (former PI) [1] Illinois Cancer Center, Jane Liu; Nguyet Le-Lindqwister (former PI) [1] Minneapolis Veterans Medical Center, Sharon Luikart [1] Saint Vincent Healthcare, Benjamin Marchello [1] Bozeman Deaconness Hospital, Benjamin Marchello [1] Benefis Healthcare-Sletten Cancer Institute, Benjamin Marchello [1] Ochsner Medical Center, Marc Matrana [1] Riverside Methodist Hospital, Timothy Moore; John P Kuebler (former PI) [1] The Mark H Zangmeister Center, Timothy Moore; John P Kuebler (former PI) [1] Mount Carmel Medical Health Center West, Timothy Moore; John P Kuebler (former PI) [1] Grant Medical Center, Timothy Moore; John P Kuebler (former PI) [1] Fort Wayne Medical Oncology and Hematology, Sreenivasa Nattam [1] Geisinger Medical Center Cancer Center Haselton, Rajiv Panikkar [1] MedStar Washington Hospital Center, George Philips [1] UC San Diego Moores Cancer Center, James Michael Randall [1] Altru Cancer Center, Grant Seeger [1] Sanford Roger Maris Cancer Center, Preston Steen; Miroslaw Mazurczak (former PI) [1] Sanford Roger Maris Cancer Center, Preston Steen [1] Boulder Community Hospital, Keren Sturtz [1] Weill Cornell Medicine, Scott Tagawa [1] Decatur Memorial Hospital, James Wade III [1] Kinston Medical Specialist PA, Peter R Watson [1] Carle Cancer Center, Yujie Zhao [1]



## Figure S1. Forest plot of progression-free survival per independent radiology review committee

HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; PFS, progressionfree survival. Data are as of September 15, 2016. All randomised patients were included in the analyses. Hazard ratios are unstratified with the exception of the analysis for all patients.

\*Eight patients in the cabozantinib group and 18 patients in the sunitinib group had unknown MET status.

## Table S1. Tumour response per investigator

	Cabozantinib (N=79)	Sunitinib (N=78)
Objective response rate (95% CI)	33% (23% - 44%)	12% (5% – 21%)
Best overall response		
Confirmed complete response	1 (1%)	0
Confirmed partial response	25 (32%)	9 (12%)
Stable disease	34 (43%)	29 (37%)
Progressive disease	14 (18%)	19 (24%)
Unevaluable or missing*	5 (6%)	21 (27%)

Data are % or n (%) and are as of September 15, 2016.

\*Unevaluable or missing for the following reasons: cabozantinib: adverse event (4), withdrew consent (1); sunitinib: adverse event (7), death (2), disease progression (2), withdrew consent (9), other (referred to hospice treatment; 1)

	Sun	Sunitinib		Cabozantinib	
	Response Assessment was PR/SD/PD (N = 60)	Response Assessment was Missing/UE (N = 18)	Response Assessment was PR/SD/PD (N = 73)	Response Assessment was Missing/UE (N = 6)	
Discontinued study treatment	60 (100%)	18 (100%)	73 (100%)	6 (100%)	
Disease progression	40 (67%)	1 (6%)	44 (60%)	0	
Adverse events	10 (17%)	6 (33%)	11 (15%)	5 (83%)	
Alternative therapy	1 (2%)	0	1 (1%)	0	
Patient off-treatment for other complicating disease	1 (2%)	0	1 (1%)	0	
Death	1 (2%)	2 (11%)	2 (3%)	0	
Withdrawn consent	4 (7%)	9 (50%)	3 (4%)	1 (17%)	
Other	1 (2%)	0	1 (1%)	0	
Age (years)	63 (45-84)	66 (31-87)	62 (40-82)	68 (53-79)	
Male	45 (75%)	12 (67%)	61 (84%)	5 (83%)	
Female	15 (25%)	6 (33%)	12 (16%)	1 (17%)	
Ethnic origin					
White	57 (95%)	18 (100%)	66 (90%)	4 (67%)	
Black or African American	2 (3%)	0	3 (4%)	0	
Other	1 (2%)	0	54 (7%)	2 (33%)	
ECOG PS					
0	28 (47%)	8 (44%)	35 (48%)	1 (17%)	
1	26 (43%)	6 (33%)	31 (42%)	2 (33%)	
2	6 (10%)	4 (22%)	7 (10%)	3 (50%)	
IMDC risk group					
Intermediate	50 (83%)	13 (72%)	61 (84%)	3 (50%)	
Poor	10 (17%)	5 (28%)	12 (16%)	3 (50%)	
Bone metastases per IxRS					
Yes	21 (35%)	7 (39%)	25 (34%)	4 (67%)	
No	39 (65%)	11 (61%)	48 (66%)	2 (33%)	
Nephrectomy	47 (78%)	13 (72%)	54 (74%)	3 (50%)	

Table S2. Study disposition and baseline characteristics by best overall response per independent radiology committee

	Sunitinib		Cabozantinib	
	Response Assessment was PR/SD/PD (N = 60)	Response Assessment was Missing/UE (N = 18)	Response Assessment was PR/SD/PD (N = 73)	Response Assessment was Missing/UE (N = 6)
Number of metastatic sites per investigator				
0	0	0	0	0
1	20 (33%)	6 (33%)	15 (21%)	2 (33%)
2	16 (27%)	4 (22%)	34 (47%)	3 (50%)
≥3	24 (40%)	8 (44%)	24 (33%)	1 (17%)

Data are n (%) or median (range). CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International metastatic renal cell carcinoma Database Consortium; IRC, independent radiology review committee; IxRS, interactive voice/web response system; PD, progressive disease; PR, partial response; SD, stable disease; UE, unable to evaluate.

Table S3.	Subsequent	anticancer	therapy

	Cabozantinib (N=79)	Sunitinib (N=78)
Any subsequent anticancer therapy	51 (65%)	50 (64%)
Radiotherapy	10 (13%)	14 (18%)
Surgery	5 (6%)	6 (8%)
Systemic therapy	48 (61%)	48 (62%)
Tyrosine kinase inhibitors	38 (48%)	37 (47%)
Axitinib	18 (23%)	16 (21%)
Pazopanib	14 (16%)	10 (13%)
Sunitinib	11 (14%)	10 (13%)
Sorafenib	1 (1%)	2 (3%)
Cabozantinib	1 (1%)	6 (8%)
Lenvatinib	1 (1%)	0
mTOR inhibitors	15 (19%)	18 (23%)
Everolimus	8 (10%)	15 (19%)
Temsirolimus	7 (9%)	4 (5%)
PD-1 checkpoint inhibitors	14 (18%)	15 (19%)
Cytokines	3 (4%)	1 (1%)

PD-1, programmed cell death-1.